Xencor, Inc Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock
Xencor, Inc (XNCR) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock of 1.12 million shares for the 12-month period ending 2016-12-31, per its 10-K filed 2018-02-28.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock · last filed 2018-02-28
- Xencor, Inc incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2013-06-30 was 12.83M shares.
- Xencor, Inc incremental common shares attributable to dilutive effect of conversion of preferred stock for fiscal 2016 was 1.12M shares.
- Xencor, Inc incremental common shares attributable to dilutive effect of conversion of preferred stock for fiscal 2013 was 13.17M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 12 month |
|---|---|---|---|---|
| 2016-12-31 | 1.12M shares 10-K · filed 2018-02-28 | |||
| 2013-12-31 | 13.17M shares 10-K · filed 2016-03-08 | |||
| 2013-09-30 | 13.72M shares 10-Q · filed 2014-11-10 | |||
| 2013-06-30 | 12.83M shares 10-Q · filed 2014-08-01 | 12.51M shares 10-Q · filed 2014-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |